PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
March 17, 2024
Share
PanGen Biotech Inc. announced a private placement to issue 737,053 shares at an issue price of KRW 5,427 for the gross proceeds of KRW 3,999,986,631 on March 18, 2024. The transaction will include participation from returning investor CrystalGenomics Invites Co., LTD. 368,527 shares, new investors Huons Co., Ltd. 184,263 shares and Hwail Pharmaceutical Co.,Ltd. 184,263 shares. The transaction has been approved by the shareholders of the company and is expected to close on March 27, 2024.
CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CRYSTALGENOMICS INVITES CO., LTD. 
